Leqembi (lecanemab-irmb) - Biogen, Eisai
A prospective, multicenter clinical study on the diagnosis of AD-related blood biomarkers in China and the evaluation of the efficacy of lencanimab (ChiCTR) - Oct 16, 2026 - P=N/A | N=550 | Not yet recruiting | Sponsor: Tianjin Huanhu Hospital; Tianjin Huanhu Hospital 
New trial • Alzheimer's Disease • CNS Disorders
https://www.chictr.org.cn/showproj.html?proj=339521
 
Oct 16, 2026
 
Prev Next